Загрузка...
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...
Сохранить в:
| Опубликовано в: : | Clin Exp Immunol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6591141/ https://ncbi.nlm.nih.gov/pubmed/30821848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13283 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|